We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Fujisawa Pharmaceutical has singed a licensing agreement with Carlsson Research,
a Swedish pharmaceutical R&D company that has developed ACR-16, a new type
of antipsychotic agent.
Rohto Pharmaceutical and Morishita Jintan have basically agreed to jointly set
up a new sales company on July 1. To be capitalized at 90 million yen ($865,000),
Medicare Systems will be owned 70 percent by Rohto and 30 percent by Morishita.
Pharmaceutical companies would get special protections from personal injury
suits in Missouri under legislation designed to lower malpractice insurance
premiums for doctors.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) recently
initiated a phased withdrawal of painkiller co-proxamol, the agency announced.
The FDA approved Mylan Laboratories' generic version of Johnson & Johnson
(J&J) subsidiary Alza's Duragesic pain patch, the same day it denied citizen's
petitions that had attempted to block generic entry to the Duragesic market.
Federal regulators are preparing to conduct much more thorough
examinations of drug products as part of an evidence-based approach to medicine
that will drive the implementation of the Medicare Rx benefit, which is slated
to take effect next year.
The FDA issued an emergency-use authorization (EUA) Jan. 31 for military use
of anthrax vaccine, marking the first time the agency has used its EUA power
since it was granted the emergency authority last summer with the passage of
Project BioShield.
JDS Pharmaceuticals and Synthon Pharmaceuticals have entered into a co-promotion
agreement for Lithobid (lithium carbonate), a leading brand of twice daily lithium
carbonate for the treatment of bipolar disorder.